Gilbert Cisneros Buys Shares of NOVT $NOVT
Key Points
- Gilbert Cisneros bought Novanta Inc. ($NOVT) stock ($1,001 - $15,000).
- The trade was disclosed by a member of the House.
- $NOVT last traded around $162.41.
Gilbert Cisneros vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Gilbert Cisneros, a member of the House, bought $1,001 - $15,000 of Novanta Inc. ($NOVT) stock on 2026-05-18, according to a periodic transaction report filed under the STOCK Act. Disclosures are filed after the trade and reflect a dollar range, not an exact amount.
Novanta Inc. ($NOVT) Stock
Novanta Inc. Earnings
Analysts Set New Price Targets
About Novanta Inc.
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.